HUE054749T2 - Kevert készítmények - Google Patents

Kevert készítmények

Info

Publication number
HUE054749T2
HUE054749T2 HUE16733592A HUE16733592A HUE054749T2 HU E054749 T2 HUE054749 T2 HU E054749T2 HU E16733592 A HUE16733592 A HU E16733592A HU E16733592 A HUE16733592 A HU E16733592A HU E054749 T2 HUE054749 T2 HU E054749T2
Authority
HU
Hungary
Prior art keywords
mixed preparations
preparations
mixed
Prior art date
Application number
HUE16733592A
Other languages
English (en)
Hungarian (hu)
Inventor
William Henry
Richard Wolf Garraway
Original Assignee
Sequessome Tech Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511478.8A external-priority patent/GB201511478D0/en
Priority claimed from GBGB1511469.7A external-priority patent/GB201511469D0/en
Application filed by Sequessome Tech Holdings Limited filed Critical Sequessome Tech Holdings Limited
Publication of HUE054749T2 publication Critical patent/HUE054749T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/618Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/02Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14Liposomes; Vesicles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Biochemistry (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE16733592A 2015-06-30 2016-06-30 Kevert készítmények HUE054749T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1511478.8A GB201511478D0 (en) 2015-06-30 2015-06-30 Blended formulations
GBGB1511469.7A GB201511469D0 (en) 2015-06-30 2015-06-30 Compositions

Publications (1)

Publication Number Publication Date
HUE054749T2 true HUE054749T2 (hu) 2021-09-28

Family

ID=56292753

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16733592A HUE054749T2 (hu) 2015-06-30 2016-06-30 Kevert készítmények
HUE16733595A HUE056161T2 (hu) 2015-06-30 2016-06-30 Többfázisú készítmények

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16733595A HUE056161T2 (hu) 2015-06-30 2016-06-30 Többfázisú készítmények

Country Status (14)

Country Link
US (5) US10744090B2 (https=)
EP (3) EP3954361A1 (https=)
JP (2) JP6851998B2 (https=)
CA (2) CA3026466A1 (https=)
DK (2) DK3316857T3 (https=)
EA (2) EA038208B1 (https=)
ES (2) ES2895910T3 (https=)
HR (2) HRP20210903T1 (https=)
HU (2) HUE054749T2 (https=)
LT (2) LT3316856T (https=)
MX (4) MX381075B (https=)
PL (2) PL3316857T3 (https=)
PT (2) PT3316856T (https=)
WO (2) WO2017001617A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
EP3411012A4 (en) 2016-02-04 2019-08-28 Alastin Skincare, Inc. COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE PROCEDURAL SKIN CARE
KR102757675B1 (ko) 2017-08-03 2025-01-20 앨러스틴 스킨케어, 인크. 피부 이완 및 신체 윤곽의 개선을 위한 조성물 및 방법
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
JP2025099708A (ja) * 2023-12-22 2025-07-03 小林製薬株式会社 外用組成物

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372296A (en) 1980-11-26 1983-02-08 Fahim Mostafa S Treatment of acne and skin disorders and compositions therefor
JPS60136511A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 高尿酸血症治療剤
JPS63501289A (ja) 1985-09-27 1988-05-19 ザ リ−ジエンツ オブ ザ ユニバ−シテイ オブ カリフオルニア リポソ−ム経皮薬剤供給系
JPS6295134A (ja) 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5498607A (en) 1990-07-30 1996-03-12 University Of Miami Treatment for hypercholesterolemia
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
WO1992003122A1 (de) 1990-08-24 1992-03-05 Gregor Cevc Präparat zur wirkstoffapplikation in kleinsttröpfchenform
US5498420A (en) 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
CA2139757C (en) 1992-07-08 2009-04-14 Gunther Maierhofer Liposomes, method of preparing the same and use thereof in the preparation of drugs
FR2714382B1 (fr) 1993-12-27 1996-02-02 Roussel Uclaf Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques.
FR2714596B1 (fr) * 1993-12-30 1996-02-09 Oreal Composition cosmétique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation.
PT789584E (pt) 1994-11-04 2002-03-28 Polymun Scient Immunbio Forsch Aplicacao de superoxido-dismutase (sod) em liposomas
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
FR2767691B1 (fr) 1997-08-27 2000-02-18 Oreal Utilisation d'une dispersion a base de vehicules lipidiques comme composition anti-inflammatoire
IL122084A (en) * 1997-10-31 1999-09-22 Lurident Ltd Formulation for personal care with mucoadhesive properties
US6534070B1 (en) 1997-11-19 2003-03-18 Schering Aktiengesellschaft Composition with azelaic acid
US6165997A (en) 1997-11-20 2000-12-26 Statens Serum Institut Phospholipids having antimicrobial activity with or without the presence of antimicrobials
CA2283574A1 (en) 1998-01-16 1999-07-22 Color Access, Inc. Stabilized whitening compositions and method of preparing same
BR9816014A (pt) 1998-09-01 2001-05-08 Idea Ag Transporte eletricamente controlado de penetrantes carregados através de barreiras
NZ332905A (en) 1998-11-19 2000-12-22 Immuno Lab Ltd Transdermal pharmaceutical composition comprising liposomal bee venom
DE69825495T2 (de) 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
GB9902527D0 (en) * 1999-02-04 1999-03-24 Phares Pharm Res Nv Compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001001962A1 (en) 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6248728B1 (en) 2000-03-10 2001-06-19 Kansas State University Research Foundation Phosphatidylcholine compositions and methods for lowering intestinal absorption and plasma levels of cholesterol
US6191121B1 (en) 2000-04-06 2001-02-20 Nicholas V. Perricone Treatment of skin damage using polyenylphosphatidylcholine
DE60122304T2 (de) 2000-04-12 2007-08-09 Liplasome Pharma A/S Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
TWI281407B (en) 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
US20030064948A1 (en) 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
PL367337A1 (pl) 2001-05-31 2005-02-21 Pharmacia Corporation Przenikająca przez skórę kompozycja selektywnego inhibitora cyklooksygenazy-2
US20050123593A1 (en) 2001-06-25 2005-06-09 Jonathan Thompson Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
CA2368656A1 (en) 2002-01-21 2003-07-21 Vasogen Ireland Limited Receptor-ligand pairing for anti-inflammatory response
AU2003233396B2 (en) 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
ES2601463T3 (es) * 2002-04-22 2017-02-15 The Procter & Gamble Company Composiciones para la higiene personal que comprenden un material que contiene cinc en una composición tensioactiva acuosa
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
CN1470234A (zh) * 2002-07-23 2004-01-28 吴翠栓 皮肤用辣椒碱脂质体制剂
US20040105881A1 (en) 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CN1703199B (zh) 2002-10-11 2010-04-28 伊迪亚股份公司 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用
JP2004131432A (ja) 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
JP2006525368A (ja) 2003-05-02 2006-11-09 アロネックス,ファーマシューティカルズ,インコーポレーテッド 脂質白金錯体およびその使用方法
EP1514539A3 (en) * 2003-05-14 2005-05-04 Signal Investment & Management Co. Micro-encapsulated topical analgesic for pain relief and sleeve comprising it
EA200600297A1 (ru) 2003-07-21 2006-08-25 Васоджен Айеленд Лимитед Лечение острого воспалительного состояния
JP2005179313A (ja) 2003-12-24 2005-07-07 Shu Uemura:Kk 皮膚化粧料用基剤の製造方法および皮膚化粧料
US7476432B2 (en) 2004-05-28 2009-01-13 Tecton Products Phosphorescent pultrusion
CA2584475A1 (en) 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
WO2006086992A2 (en) 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
US20070042008A1 (en) 2005-08-18 2007-02-22 Bodybio, Inc. Compositions containing phosphatidylcholine and essential fatty acids
UA89545C2 (uk) 2005-08-29 2010-02-10 Сепсикюр Л.Л.К. Спосіб лікування чи попередження станів, викликаних грампозитивними бактеріями
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
NZ569068A (en) 2005-12-20 2011-11-25 Cenestra Llc Omega 3 fatty acid formulations of EPA and DHA
JP5009547B2 (ja) 2006-03-31 2012-08-22 株式会社コーセー 顔料とリポソームを含む化粧料
US7544375B1 (en) 2006-06-12 2009-06-09 Swiss Skin Repair, Inc. Composition
WO2008039989A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof
CA2664944C (en) 2006-09-28 2016-06-14 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
JP4732307B2 (ja) 2006-11-20 2011-07-27 株式会社アンズコーポレーション ナノエマルション及びそれを配合した化粧料
US20100130611A1 (en) 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
EP1938801A1 (en) 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
ITVR20080006A1 (it) 2008-01-23 2009-07-24 David Ceretta Apparato per la realizzazione di elementi d'impasto
ES2335636B1 (es) * 2008-02-29 2011-05-11 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica de micelas mixtas.
JP2009256331A (ja) 2008-03-25 2009-11-05 Nagase Chemtex Corp 高尿酸血症、又は痛風の予防、改善、又は治療剤
US20100105139A1 (en) 2008-10-27 2010-04-29 Remco Alexander Spanjaard Ligand Targeted Nanocapsules for the delivery of RNAi and other Agents
KR20110128283A (ko) 2009-02-05 2011-11-29 타겟티드 딜리버리 테크놀러지스 리미티드 미생물체의 증식 및 생존도를 감소시키는 방법
CN105434353A (zh) 2009-06-03 2016-03-30 斯昆申技术控股有限责任公司 用于治疗深部组织疼痛的制剂
GB2486371A (en) 2009-08-21 2012-06-13 Targeted Delivery Technologies Ltd Vesicular formulations
EP2382994A1 (en) 2010-04-26 2011-11-02 Maurizio Victor Cattaneo Ligand targeted nanocapsules for the delivery of RNAi and other agents
WO2011162802A1 (en) 2010-06-21 2011-12-29 Virun, Inc. Compositions containing non-polar compounds
US20120045405A1 (en) 2010-08-18 2012-02-23 Gilman Miles E Under eye cream
WO2012148891A1 (en) 2011-04-29 2012-11-01 Evonik Degussa Corporation Peptide-lipid conjugates and uses thereof
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
AU2014298426B2 (en) * 2013-07-31 2019-07-18 Sequessome Technology Holdings Limited Vesicles
ES2895910T3 (es) 2015-06-30 2022-02-23 Sequessome Tech Holdings Limited Composiciones multifásicas
JP2022535143A (ja) * 2019-06-04 2022-08-04 アクアヴィット ファーマシューティカルズ,インコーポレイテッド マイクロチャネル技術を使用してヒアルロン酸で皮膚をマイクロフィルするための方法および組成物

Also Published As

Publication number Publication date
US20190167588A1 (en) 2019-06-06
CA3026484A1 (en) 2017-01-05
US10744090B2 (en) 2020-08-18
EA038208B1 (ru) 2021-07-23
MX381075B (es) 2025-03-12
US20220370353A9 (en) 2022-11-24
PL3316856T3 (pl) 2021-10-25
CA3026466A1 (en) 2017-01-05
US20210023007A1 (en) 2021-01-28
ES2879383T3 (es) 2021-11-22
US20240099976A1 (en) 2024-03-28
MX2018000021A (es) 2018-03-15
HK1254980A1 (zh) 2019-08-02
EP3316856B1 (en) 2021-04-07
WO2017001625A1 (en) 2017-01-05
MX2021003510A (es) 2021-05-27
MX2018000024A (es) 2018-06-27
PT3316856T (pt) 2021-07-06
HRP20210903T1 (hr) 2021-09-17
JP2021091730A (ja) 2021-06-17
HUE056161T2 (hu) 2022-01-28
LT3316856T (lt) 2021-07-12
EP3954361A1 (en) 2022-02-16
MX382034B (es) 2025-03-13
DK3316856T3 (da) 2021-06-28
EP3316857B1 (en) 2021-08-04
US11547665B2 (en) 2023-01-10
EP3316857A1 (en) 2018-05-09
PL3316857T3 (pl) 2022-01-31
EA201890119A1 (ru) 2018-07-31
JP6851998B2 (ja) 2021-03-31
EA201890120A1 (ru) 2018-07-31
EA038613B1 (ru) 2021-09-23
PT3316857T (pt) 2021-11-03
DK3316857T3 (da) 2021-10-18
EP3316856A1 (en) 2018-05-09
JP2018522876A (ja) 2018-08-16
MX2021004766A (es) 2022-11-07
HK1254979A1 (zh) 2019-08-02
HRP20211669T1 (hr) 2022-02-18
US20180311148A1 (en) 2018-11-01
LT3316857T (lt) 2021-11-25
ES2895910T3 (es) 2022-02-23
US20210007989A1 (en) 2021-01-14
WO2017001617A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
IL281863A (en) Pharmaceutical compositions comprising meloxicam
IL282304A (en) Topical pharmaceutical compositions
IL259576A (en) Compositions and methods for immunooncology
IL254516B (en) Proteins specific for cd137
HRP20180501T1 (hr) Pripravci koje sadrže bakterijske sojeve
EP3374114A4 (en) WORKBENCH
LT3250239T (lt) Kapsidė
EP3337502A4 (en) STABLE ANTI-IFNAR1 FORMULATION
EP3258822C0 (en) SMART MIXING SYSTEM
HUE058288T2 (hu) Pridopidin módosított hatóanyag-leadású készítményei
HUE054344T2 (hu) Gyógyászati készítmények AZD9291 tartalommal
IL256939B (en) Rapid-acting insulin compositions
HUE053347T2 (hu) Glikopeptid-készítmények
KR102494289B9 (ko) 활성 혼합물
LT3386954T (lt) Dimeriniai kontrastiniai agentai
HUE045024T2 (hu) Poliamid készítmények
IL256381A (en) Cryoprecipitate compositions and methods of preparation thereof
EP3345473A4 (en) HARVESTER
SI3310340T1 (sl) Formulacija visoke koncentracije
HUE055312T2 (hu) Közegkeverõ kamra
HUE054096T2 (hu) Krémesítõ készítmény
DK3364753T3 (da) Blandevogn
EP3351087A4 (en) HARVESTER
HUE053624T2 (hu) Ciklosporint tartalmazó készítmények
HUE054749T2 (hu) Kevert készítmények